Intraperitoneal -Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

Author： Berek J.S. Markman M. Blessing J.A. Kucera P.R. Nelson B.E. Anderson B. Hanjani P.

Publisher： Elsevier

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.74, Iss.1, 1999-07, pp. : 48-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Study of Intraperitoneal Cisplatin and Thiotepa in Residual Ovarian Carcinoma: A Gynecologic Oncology Group Study

By Feun L.G. Blessing J.A. Major F.J. DiSaia P.J. Alvarez R.D. Berek J.S.

Gynecologic Oncology, Vol. 71, Iss. 3, 1998-12 ,pp. : 410-415

Elsevier

Access to resources Recommend Favorite

Intraperitoneal Interferon- in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

By Berek J.S. Markman M. Stonebraker B. Lentz S.S. Adelson M.D. DeGeest K. Moore D.

Gynecologic Oncology, Vol. 75, Iss. 1, 1999-10 ,pp. : 10-14

Elsevier

Access to resources Recommend Favorite

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal ³²P or intravenous cyclophosphamide and cisplatin - a Gynecologic Oncology Group study

By Naumann R. Wendel

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 33-34

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

By Manetta A. Blessing J.A. Hurteau J.A.

Gynecologic Oncology, Vol. 68, Iss. 1, 1998-01 ,pp. : 45-46

Elsevier

Access to resources Recommend Favorite

A Phase II Trial of CI-958 in Recurrent Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study

By Hoffman M.A. Blessing J.A. Nunez E.R.

Gynecologic Oncology, Vol. 81, Iss. 3, 2001-06 ,pp. : 433-435

Elsevier

Access to resources Recommend Favorite